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ABSTRACT
The silver(I) complex [Ag(eppe)2]NO3 (eppe Et2PCH2CH2PPh2) is shown by X-ray
crystallography to be tetrahedral with Ag PEt2 and Ag P Ph2 bond lengths of 2.482 and 2.518/,
respectively. The complex is selectively antimitochondrial and inhibits the growth of a number of
yeast strains in non-fermentable media at concentrations as low as 2.5 IM and induces the
mitochondrial mutation petite. The effect is largely reversed by the presence of aspirin. The complex
is shown to be stable in the cell culture media and in the presence of glutathione, but readily reacts
with disulfides of oxidized glutathione and serum albumin. Surprisingly, neither [Au(eppe)2]CI nor
[Au(dppe)2]CI (dppe Ph2PCH2CH2PPh2) showed any mitochondrial selectivity in the same
screening protocol.
INTRODUCTION
The potent antibacterial properties of silver compounds have been known for some time.
For example, silver sulfadiazene has been used as a topical burn treatment to prevent bacterial
infection.I,2 and has been reported to have antifungal, antiherpes virus and antitreponemal
activity.3 [Ag(dppe)2]NO3 and [Ag(depe)2]NO3 were also found to have antibacterial and antifungal
activity against C. albicans with activity comparable to fungizone, in a defined medium.4 However,
the antifungal activity was lost in Sabouraud’s broth medium, as was the antitumour activity in
media containing fetal calf serum. This illustrates a general problem with the development of silver
compounds as drugs, viz. their reactivity in physiological fluids, with strong binding to components
of the fluid, or sometimes precipitation of Ag(I) salts such as AgCI preventing uptake of silver. The
success of silver sulfadiazene, which is polymeric in the solid state with distorted trigonal
bipyramidal coordination geometry,2 is attributed to the slow release of Ag(I) ions which function as
the bactericide at the wound site.5 The development of resistance to antibacterial silver
preparations appears to be related to the ability of resistant bacteria to bind silver more strongly
than chloride,6 and hence the silver is unavailable to these bacteria.
Of the 100 silver compounds reported to have been tested by the National Cancer Institute
for anticancer activity, only 5 had marginal activity at best.7 Interestingly, the binuclear silver
complex [(l-dppe)(AgNO3)2] was inactive against P388 leukemia cells,8 which may be due to the
increased kinetic reactivity of the linear silver complex compared to the tetrahedral complex. In an
attempt to overcome these difficulties, some success has been achieved in reducing the kinetic
reactivity of silver(I) complexes by imposing tetrahedral geometry at the metal centre, which tends
to shield the metal from competing ligands,7 thereby potentially allowing better access of the silver
complex to the target site. Tetrahedral Ag(I) diphosphine complexes have been shown to be both
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potent cytotoxic and antitumour agents.7 The silver(I) complexes [AgL2]NO3 {L
Ph2PCH2CH2PPh2 (dppe); Et2PCH2CH2PEt2 (depe); cis-Ph2PCH=CHPPh2 (dppey)} are cytotoxic
towards B16 melanoma cells in vitro with IC50 values of ca. 4 #M (IC50 is the concentration required
to inhibit cloning efficiency by 50 %), which is comparable to the extensively studied Au(I) analogue.
The complexes were also active against intraperitoneal P388 leukemia in mice and M5076
reticulum sarcoma.4 Cancer cells frequently possess respiratory defective mitochondria,9 and it has
been suggested that these may prove to be potential targets for novel antitumour agents. 10 A
screening protocol for potential anticancer drugs based on the yeast mitochondrial system has been
reported.11 The yeast cell is now widely accepted as a suitable model of the eukaryotic cell with
mitotic and meiotic cycles and with mitochondria similar in all fundamental respects to those of
mammalian cells.
We now report that the tetrahedral silver diphosphine complex [Ag(eppe)2]NO3 (eppe
Et2PCH2CH2PPh2) shows selective, primary antimitochondrial activity in yeast cells, and also
discuss the chemistry of this complex in solution and in the solid state.
MATERIALS AND METHODS
Chemicals
Et2PCH2CH2PPh2 was purchased from Strem Chemical Inc.. All other chemicals were
supplied by the Aldrich Chemical Co. and were used without further purification. Bovine serum
albumin (fraction V, fatty acid free) was obtained from Boehringer Mannheim GmbH.
Synthesis
Bis(1-(diethylphosphino)-2-(diphenylphosphino)ethane)silver(I) nitrate.12
Under argon, silver nitrate (73 mg, 0.4 mmol) was dissolved in a solution of 1-
(diethylphosphino)-2-(diphenylphosphino)ethane (260 mg, 0.9 mmol) in chloroform (10 mL;
degassed by purging with argon). After 2 h all the material had dissolved, and the mixture was
stirred overnight. The mixture was filtered and the solvent removed in vacuo to give a colourless oil
which was crystallized by trituration with ice-cold ether (286 mg, 86 %, m.p. 134-152 C).
Calculated for C36H48AgNO3P4 C: 55.8 %, H: 6.3 %, N: 1.8 %, P: 16.0 %; Found C: 55.4 %, H:
6.4 %, N: 1.6 %, P: 15.6 %
NMR Measurements
31p{1H}.nmr spectra were obtained on a JEOL GSX-500 spectrometer operating at 202.35
MHz, or a JEOL GSX-270 spectrometer operating at 109.35 MHz, with broad band proton
decoupling. Unless otherwise noted, samples were contained in 5 mm tubes and spectra were
recorded at ambient temperature (ca. 22 oC) except for the reactions involving serum albumin,
which were recorded at 37 C. Typical accumulation conditions were 3 18 kHz spectral width, 0.7
1.4 s acquisition time, 15 30s pulse width, 2 s relaxation delay and 16 K data points. All spectra
were referenced to 85 % H3PO4 (external). 1H-nmr spectra were recorded on a JEOL GSX-270
spectrometer operating at 270.16 MHz, typical accumulation conditions were a 3.2 kHz spectral
width, 2.5 s acquisition time, 5 #s pulse width, 2 s recycle delay and 16 K data points. 1H spectra
were referenced to TSP via residual solvent resonances.
Variable temperature 31p nmr spectra were collected for 65 mM solutions of
[Ag(eppe)2]NO3 in CDCI3. For reactivity studies, typically the complex (ca. 5 mg) was dissolved in
200 IL dmso, and was added to 500 IL D20, 1 M NaCI, glutathione (oxidized or reduced) solution
in D20, albumin solution in deuterated phosphate solution or yeast culture media, to give a final
concentration of the complex of ca. 9 mM. Solutions of glutathione (oxidized or reduced) were
prepared by dissolving the required amount (1,4 or 8 equivalents) in D20 and were studied directly
(pH* ca. 5) or with adjustment of pH* to ca. 7 with 0.2 M NaOD. Bovine serum albumin solutions
were prepared by dissolving the protein in 10 mM phosphate solution in D20 (final pH* ca. 6.9) to
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give protein concentrations of 0.63 or 2.0 mM. Yeast extracts were prepared as described for the
biological studies and spectra of these solutions were collected without deuterium lock. Solutions of
yeast extracts were pale yellow, and all other solutions were colourless, After addition of the silver
complex, samples were clear, or slightly cloudy, and were suitable for examination by 31p{1H} nmr,
except albumin samples, which immediately yielded a thick white precipitate. These samples were
centrifuged and the supernatants studied by 31 p{1H} nmr.
Crystallography
Colourless prisms suitable for single crystal X-ray diffractometry were obtained upon
standing a 9 mM solution of the [Ag(eppe)2]NO3 in dmso: D20 (2:5 v/v).for one week.
Crystal Data: C36H48AgNO3P4, M 774.5, triclinic, a 13.06(2), b 16.60(2), c 19.18(2) . a
105.01 (3), 91.77(5), 7= 90.27(4), space group , Z 4, U 3770(9) .3, Dc 1.365 Mg m-3,
F(000) 1608, I(Mo-K) 20.285 cm- 1.
Data Collection. Unit cell dimensions and intensity data were obtained at 293 K using an Enraf-
Nonius diffractometer and area detector with graphite monochromated Mo-K radiation, following
previously described procedures13 (D 50 mm, 20D 23). A total of 12000 reflections were
measured, of which 8740 were unique.
Biology
The yeast Saccharomyces cerevisiae is a faculative anaerobe and as such can grow in the
absence of mitochondrial respiratory function provided the glycolytic cycle (glucose metabolism) is
operative in generating ATP. Haploid yeast strains of Saccharomyces cerevisiae were used from a
standard collection in our laboratory. The yeast culture media contained 1% yeast extract (Difco)
and either 2% glucose (YED) or 4% glycerol (YEG) as the carbon and energy sources. Where solid
medium was required, 1% agar (Difco) was added to the medium.
CONTROL
Figur 1. Cultures of yeast strain D75 in fermentable (YED) medium showing dependence on dose
of [Ag(eppe)2]NO3. The small white colonies are those of the petite mutation. The larger colonies
are normal cells.
113Vol. 2, No. 2, 1995 [Ag(I) (Et2PCIt2CH2PPh2)2]NO3
An Antimitochondrial Sih,er Complex
Drop inocula of cells from 15 strains of yeast were plated on either YEG- or YED-agar
media containing [Ag(eppe)2]NO3. Typically the complex was dissolved in dmso and was added to
the medium to the required concentrations (2.6, 6.5 and 13 #M). Control tests showed dmso had
little or no effect on the growth of cells at the concentrations used. Growth was recorded after 2
days incubation at 30 C. Treated cultures growing on glucose medium were sampled and cells
plated on YED-agar. Colonies of the mitochondrial mutation petite14 that appeared were identified
as small white colonies compared to the larger, creamy colonies of unaffected strains, making
scoring unambiguous (Figure 1). Respiratory deficiency was verified by failure to grow when
transferred to YEG medium. The effect of aspirin was studied in both the YEG and YED media at a
concentration of 13 #M [Ag(eppe)2]NO3 (10 lg/mL) and 5.4 mM aspirin (1 mg/mL) in the media,
and were scored after 5 days. Toxicity was measured in terms of cell death.
RESULTS
Chemical Studies
The light stable silver complex, [Ag(eppe)2]NO3, was prepared by a similar procedure to
that reported earlier, 12 and was found to be stable in dmso:water (2:5 v/v) solution for at least 24
hours by 31p{1H} nmr. The spectrum at 295 K consists of a complicated multiplet pattern centered
at 2.3 ppm in this solvent, and 2.0 ppm in CDCI3. The mulitplet structure was resolved by cooling
the solution in CDCI3 to 258 K. The spectrum of the complex in M NaCI remained unchanged for
at least several hours.
(5(31 p) / ppm
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Figure 2. 31p{1H} nmr spectrum of [Ag(eppe)2]NO3 in YEG medium, the spectrum is
identical to that of the complex in the absence of culture medium.
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No changes were evident in the spectra of the complex in both the fermentable and non-
fermentable yeast extracts, although an additional resonance at ca. 0.5 ppm was observed,
assignable to phosphate in the media (Figure 2). Spectra from mixtures of the complex and reduced
glutathione at pH* 5 or 7 showed the presence of unreacted silver complex, in addition to two minor
resonances at 62.5 and 40.3 ppm, attributable to traces of Et2P(O)CH2CH2P(O)Ph2. When a
solution of [Ag(eppe)2]NO3 in dmso was added to 0.63 mM or 2.0 mM solutions of bovine serum
albumin in 10 mM phosphate solution (pH* 7), a thick white precipitate formed immediately, which
was removed by centrifugation. The spectrum of the supernatant showed two doublets at 62.5 and
40.3 ppm J 53 Hz, consistent with the formation of Et2P(O)CH2CH2P(O)Ph2. On addition of the
complex to a solution containing or 4 mol equivalents of oxidized glutathione, 31p{1H} nmr
spectroscopy indicated the presence of both the diphosphine dioxide, as for albumin, and a multiplet
centred at 2.0 ppm, assigned to unreacted silver complex. Complete reaction of the silver complex
was observed when 8 mol equivalents of oxidized glutathione were used. 1H nmr spectra indicated
the presence of reduced glutathione in the reaction mixture.
Molecular Structure
The single crystal X-ray structure was solved by the heavy atom method, 16 and was refined
by full matrix least squares methods (SHELX-93). 17 Absorption corrections were applied at the
isotropic refinement stage using the DIFABS procedure, 18 adapted for FAST geometry. 19 H atoms
were allowed to ride on their parent carbon atoms in their calculated positions (Calkyl- H 0.97,
Caryl H 0.93 ,/k). The final R1 and WR2 values were 0.0472 and 0.1229, respectively. Non-
hydrogen atom coordinates and equivalent isotropic thermal parameters are displayed in Table 1.
Table 1. Atomic coordinates (x 104) and equivalent isotropic displacement parameters (,&2 x 103)
for C36H48AgNO3P4 U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.
x y z U(eq)
Ag(I) 2281(1) 2091(1) 4604(1) 21(1)
P(11 1169(1 2543(1 5686(1 20(1
P(12) 2955(1) 3124(1) 3919(1) 23(1)
P(13) 838(1) 1085(1) 4053(1) 22(1)
P(14) 4095(1) 1737(1) 4802(1) 29(1)
N(11 2706(3) 8645(3) 4887(2) 29(1
O(11 2634(3) 8397(3) 5456(2) 43(1
O(12) 2813(3) 9453(3) 4917(2) 44(1)
O(13) 2672(3) 8076(3) 4289(2) 50(1
C(11) 1923(3) 1130(4) 6172(3) 25(1)
C(12) 2033(4) 589(4) 6646(3) 27(1)
C(13) 1594(4) 834(4) 7318(3) 29(1
C(14) 1032(4) 1603(4) 7508(3) 28(1
C(15) 903(3) 2137(4) 7035(2) 25(1
C(16) 1361(3) 1901(3) 6361(2) 21(1)
C(17) 1694(4) 4075(4) 6788(3) 33(1
C(18) 1660(5) 4962(4) 7146(3) 47(2)
C(19) 929(5) 5499(5) 6934(4) 53(2)
C(110) 236(5) 5144(5) 6375(3) 47(2)
C(111 267(4) 4250(4) 6024(3) 35(1
C(112) 996(4) 3686(4) 6214(3) 27(1
C(113) 2310(4) 4684(4) 4870(3) 34(1
C(114) 2209(4) 5591(4) 5137(3) 39(1)
C(115) 2726(4) 6168(4) 4835(3) 38(1)
C(116) 3364(4) 5836(4) 4261 (3) 38(2)
C(117) 3485(4) 4926(4) 3999(3) 32(1
C(118) 2955(4) 4322(4) 4295(2) 25(1
C(119) 2041 (3) 3654(4) 2728(3) 27(1
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Table 1 (cont.). Atomic coordinates (x 104) and equivalent isotropic displacement parameters
x 103) for C36H48AgNO3P4.
x y z U(eq)
116
C(120) 1672(4) 3485(4) 2011(3) 32(1)
C(121) 1780(4) 2665(4) 1537(3) 29(1)
C(122) 2250(4) 1985(4) 1773(3) 33(1)
C(123) 2600(4) 2150(4) 2486(3) 32(1
C(124) 2516(3) 2976(4) 2970(2) 24(1)
C(125) -117(3) 2143(4) 5300(3) 30(1)
C(126) 75(4) 1207(4) 4796(3) 28(1
C(127) 4807(3) 2611(4) 4512(3) 28(1)
C(128) 4326(3) 2826(4) 3825(3) 29(1
C(129) 74(4) 1342(4) 3315(3) 32(1
C(130) -280(5) 2308(4) 3483(3) 44(2)
C(131) 966(4) -113(4) 3761(3) 34(1)
C(132) 1646(6) -443(6) 3118(4) 76(2)
C(133) 4627(4) 1881(5) 5734(3) 52(2)
C(134) 4259(5) 2679(5) 6277(3) 59(2)
C(135) 4680(4) 689(4) 4342(3) 44(2)
C(136) 4625(5) 478(5) 3526(3) 59(2)
Ag(2) 2964(1) 7526(1) 112(1) 21(1)
P(21) 1881(1) 6297(1) 367(1) 19(1)
P(22) 4157(1) 7224(1) -929(1) 19(1)
P(23) 1310(1) 8292(1) 88(1) 25(1)
P(24) 4479(I) 8299(1) 843(1) 21(1)
N(21) 7675(4) 9246(4) 393(2) 39(1)
O(21) 7084(3) 9740(3) 161(3) 58(1)
0(22) 8221 (4) 8740(4) -34(3) 84(2)
0(23) 7699(4) 9222(5) 1025(3) 91 (2)
C(21 2352(4) 6984(4) 1839(3) 26(1
C(22) 2293(4) 7062(4) 2574(3) 32(1)
C (23) 1612(4) 6525(4) 2818(3) 32(1)
C(24) 989(4) 5925(4) 2318(3) 29(1
C(25) 1041(3) 5847(4) 1584(3) 25(1)
C(26) 1742(3) 6370(3) 1332(2) 20(1
C(27) 1668(3) 4765(4) -803(3) 26(1
C(28) 1735(4) 3882(4) -1138(3) 31(1)
C(29) 2079(3) 3271(4) -763(3) 30(1)
C(210) 2366(4) 3598(4) -31(3) 29(1)
C(211) 2298(3) 4487(4) 312(3) 26(1)
C(212) 1928(3) 5105(3) -64(2) 20(1)
C(213) 5549(4) 5964(4) -1726(2) 28(1)
C(214) 5900(4) 5118(4) -1997(3) 33(1)
C(215) 5420(4) 4402(4) -1843(4) 51 (2)
C(216) 4576(5) 4559(5) -1400(5) 80(3)
C(217) 4226(4) 5405(4) -1131 (4) 48(2)
C(218) 4692(3) 6129(4) -1287(3) 24(1)
C(219) 3514(4) 8490(4) -1618(3) 31(1)
C(220) 3144(4) 8803(5) -2189(3) 42(2)
C(221) 3024(4) 8233(5) -2877(3) 45(2)
C(222) 3271 (4) 7355(5) -2990(3) 41 (2)
C(223) 3658(4) 7032(4) -2417(3) 29(1
C(224) 3788(3) 7599(3) -1725(2) 20(1)
C(225) 578(3) 6577(4) 81(3) 24(1)
C(226) 367(3) 7554(3) 357(3) 25(1)
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Table 1 (cont.). Atomic coordinates (x 104) and equivalent isotropic displacement parameters
(/,2 x 103) for C36H48AgNO3P4.
x y z U(eq)
C(228) 5300(3) 7917(4) -529(2) 26(1
C(229) 820(5) 8426(6) -780(4) 76(3)
C(230) 945(6) 7613(7) -1412(4) 90(4)
C(231) 1074(7) 9348(6) 705(6) 117(4)
C(232) 680(14) 9603(8) 1262(6) 249(11
C(233) 4903(4) 8114(4) 1722(3) 30(1)
C(234) 5955(4) 8482(5) 2034(3) 40(2)
C(235) 4661(4) 9501(4) 966(3) 28(1)
C(236) 4027(4) 10071 (4) 1554(3) 44(2)
Table 2. Selected bond lengths (A) and angles for each molecule in the asymmetric unit of
[Ag(eppe)2]NO3.
molecule 1 molecule 2
Bond lengths
Ag- P(1)
Ag- P(2)
Ag- P(3)
Ag- P(4)
P(1)- C(25)
P(2)- C(28)
P(3)- C(26)
P(4)- C(27)
C(25) C(26)
C(27) C(28)
Bond Angles
2.520(3) 2.533(3)
2.501(2) 2.519(3)
2.472(3) 2.477(3)
2.475(4) 2.502(3)
1.853(5) 1.860(5)
1.855(5) 1.862(5)
1.858(5) 1.856(5)
1.857(5) 1.840(5)
1.531(8) 1.508(8)
1.557(7) 1.531(7)
P(2)- Ag- P(1) 124.84(8) 121.19(7)
P(3)- Ag- P(1) 85.04(10) 84.67(11)
P(4)- Ag- P(1) 118.25(9) 127.07(7)
P(3)- Ag- P(2) 118.19(8) 122.66(8)
P(4)- Ag- P(2) 86.14(8) 84.90(11
P(4)- Ag- P(3) 129.36(9) 121.28(10)
C(25) P(1 )- Ag 102.4(2) 101.8(2)
C(26) P(3)- Ag 104.0(2) 104.0(2)
C(27) P(4)- Ag 103.1 (2) 100.9(2)
C(28) P(2)- Ag 103.0(2) 102.1 (2)
C(26) C(25) P(1) 111.4(4) 111.7(3)
C(25) C(26) P(3) 114.5(3) 114.4(3)
C(28) C(27) P(4) 113.4(3) 111.4(3)
C(27) C(28) P(2) 112.9(3) 110.4(3)
The complex crystallizes with 2 molecules in the asymmetric unit. The Ag in each case is
coordinated to four phosphorus atoms with distorted tetrahedral geometry at silver. The Ag PEt2
bond lengths of 2.482 ,&, (av) are slightly shorter than the Ag PPh2 lengths of 2.518 ,&, (av). The
intra-ligand Et2P-Ag-PPh2 bond angles are all approximately 85o. Selected bond lengths and
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angles for both molecules in the asymmetric unit are displayed in Table 2. Thermal parameters
indicate minor disorder in one of the ethyl groups of one molecule. Figure 3 depicts a projection of
the asymmetric unit down the x-axis.
Biological Studies
A dose-dependent response was observed in the yeast cultures. Growth was inhibited on
the non-fermentable glycerol (YEG) medium at concentrations as low as 2.5M (2 g/mL) but
growth proceeded in glucose containing cultures in the presence of the complex. Cells plated on the
fermentable D-glucose (YED) medium showed induction of the mitochondrial mutation petite in most
strains (Figure 1). Although growth was inhibited on the YEG medium in the presence of the
complex, normal growth was observed when aspirin was also present. On the YED medium, growth
was observed in the presence or absence of aspirin.
DISCUSSION
Structure and Reactivity of[Ag(eppe)2]N03
In the solid state, [Ag(eppe)2]NO3 crystallizes with two molecules of opposite chirality in the
asymmetric unit. In each case, the silver possesses flattened tetrahedral geometry. There are two
types of Ag P bond in the complex, with the Ag PPh2 bonds (2.501 2.533 ) being slightly
longer than the Ag PEt2 bonds (2.472 2.502/,), PEt2 being the more basic phosphorus in the
ligand.20 The structure of a number of tetrahedral silver complexes with phosphines have been
reported, and the Ag PEt2 distances are similar to those observed for
[Ag(Me2PCH2CH2PMe2)2]BPh4 (2.496 /,, average).21 By comparison, the longer Ag PPh2
distances in [Ag(eppe)2]NO3 are similar to the Ag P distance reported forthe related dppe
complexes such as [Ag(dppe)2]NO3 (2.513 /, average)22 and the dimeric complex
[Ag2(dppe)4](NO3.CH3OH)2, which contains both bridging and chelating ligands (2.544 ,
average).23 Both types of bond length are shorter than the Ag P distance of 2.64 2.75 , reported
for a number of [Ag(PPh3)4]+ complexes, although it is thought that the Ag P distance is
lengthened in these cases due to steric crowding of the phenyl rings, which is less severe in the
bidentate diphosphines.24 Curiously the related complex, [Ag(cis-
Ph2PCH=CHPPh2)2][SnPh3(NO3)2]has a shorter Ag -P distance of 2.473 ]k (average),25 despite
the lower pKa for this diphosphine.20 The restricted bite of the eppe diphosphine ligand imposes a
small intra-ligand Et2P Ag PPh2 angle (84.5 86.5) on the complex and results in opening of the
inter-ligand P Ag P angles. This is the major cause of distortions from ideal geometry, as for
other silver complexes with bidentate phosphines.2123, 25
In chloroform solution, the complicated splitting pattern of the 3p{1H} nmr spectrum is
consistent with the coupling of 4 magnetically inequivalent phosphorus atoms coupled to the two
spin -1/2 isotopes 107Ag and 109Ag (51% and 49 %, respectively) in an [AA’BB’X]2 spin system. In
an earlier study12 we estimated the two j(109Ag-31p) coupling constants to be -290 and -232 Hz
from analysis of a 109Ag spectrum recorded by the use of a 109{31p} DEPT sequence. The
presence of the two unequal Ag P couplings is consistent with the unequal Ag P bond lengths
shown in the x-ray structure, and we now assign the larger (-290 Hz) coupling constant to the
shorter Ag PEt2 bonds andf the -232 Hz coupling to the Ag PPh2 bonds. The complex undergoes
dynamic ligand exchange and a metal centred inversion process, so that in CDCI3 solutions above
235 K only one set of proton nmr resonances were observed for both the ethyl and phenyl groups in
the two chiral molecule.26
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Figure 3. A: Molecular structure of both [Ag(eppe)2]NO3 molecules in the asymmetric unit.
Each Ag has flattened tetrahedral geometry, the molecules differ in chirality and in orientation of the
substituents at phosphorus.
B: Numbering system, numbers are prefaced by for molecule 1, and 2 for
molecule 2.
The studies reported here show that [Ag(eppe)2]NO3 is stable in aqueous solution as well
as in M NaCI solution, although in analogous Ag(I) complexes with monodentate phosphines,
chloride ion binds to silver with the exclusion of a fourth ligand.27 This is perhaps a reflection of the
enhanced thermodynamic and kinetic stability of the bis-chelated silver diphosphine complexes
compared to complexes with monodentate phosphineso The complex also remains intact in media
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containing either glycerol or glucose yeast extracts. Therefore it is likely that the tetrahedral
complex is responsible for the biological activity. Further reactivity studies showed that the complex
was not destroyed by reduced glutathione in aqueous media over several hours, indicating slow or
little reaction with this thiol. However, the complex did react rapidly with bovine serum albumin,
giving rise to the immediate formation of a thick white precipitate, presumably denatured protein.
The denatured protein may contain reduced disulfide bridges since the oxidized ligand,
Et2P(O)CH2CH2P(O)Ph2, was detected as product by comparison with known chemical shifts.15
Serum albumin is known to oxidize phosphines. The auranofin analogues [(Et3P)2Au]CI and
[pri3PAuSATg], (HSATg 2,3,4,6-tetra-O-acetyl-l-thio-I-D-glucose) both react with the disulfide
linkages of albumin to give phosphine oxide and free thiol groups.28 [Au(eppe)2]CI is also oxidized
by serum albumin, giving Et2P(O)CH2CH2P(O)Ph2 and denatured protein.15 Similar results were
obtained when the complex was added to solutions of oxidized glutathione, which also contains a
disulfide bond, and reduced glutathione was detected as a product. This poses a potential problem
with drug delivery, as the Ag(I) complex would need to be protected from endogenous disulfides by
a suitable formulation.
Antimitochondrial Studies
The yeast Saccharomyces cerevisiae is a faculative anaerobe, so cells are able to divide
and grow in the absence of oxygen respiration processes, provided glucose is available. In this
case, fermentation (or glycolysis) provides sufficient ATP to sustain growth. On the other hand, ATP
can be produced in the presence of oxygen by the tricarboxylic acid (TCA, or Krebs) cycle and
respiratory chain of the mitochondria. [Ag(eppe)2]NO3 inhibited the growth of all 15 strains of yeast
used in this test. At a concentration of < 13 #M (10 lg/mL) on the non-fermentable medium, the
cells were unable to process the TCA cycle metabolite, glycerol, indicating that the mitochondria
were non-functional, and that no ATP was produced. The dose response depends on the strain,
with some strains being inhibited at concentrations as low as 2.5 #M (2 #g/mL). Therefore,
[Ag(eppe)2]NO3 is displaying primary antimitochondrial activity and is affecting mitochondrial
function without major disruption of other cellular functions.
The second phase of the testing protocol involved the assessment of the mutagenicity of
the silver compound. Here the yeast cultures were grown on a fermentable medium (containing
glucose), and were then screened for induction of the well known mitochondrial mutation petite. This
is a mitochondrial mutation which arises with a high spontaneous frequency (about 1%) and is
characterized by the loss of segments of mitochondrial DNA, presumably through a defect in the
replication mechanism. 14 This results in failure of cytochromes a + a3 and b to be synthesized by
the mitochondrial system. As noted earlier, growth of petite cells can proceed on glucose medium
until the glucose is depleted, after which time no growth is possible. This results in small white
colonies of the petite mutation, rather than the larger creamy colonies of normal cells. Identification
of these is unambiguous, the white colour is due to the lack of cytochromes a + a3 and b in these
cells. [Ag(eppe)2]NO3 induced a high frequency of the petite mutation (Figure 1). The combination
of these two tests indicates that [Ag(eppe)2]NO3 is an antimitochondrial agent and potential
antitumour drug. These studies indicate that the complex is able to selectively target mitochondria,
and inhibit the process of respiration. It now remains to be seen if [Ag(eppe)2]NO3 is able to
selectively kill tumour cells as is the case for the metal drug cisplatin, currently in clinical use in
cancer treatment.
When aspirin was present in the growth medium with the silver complex, the cells grew
normally, and both the toxic and mutagenic effects of the silver compound were lost. Although the
reasons for this are unclear, it is an effect that has been observed in previous studies of
antimitochondrial compounds in our system.29 it is suggested that aspirin prevents the penetration
of the compounds into the cell by altering membrane permeability, thus protecting the mitochondria.
The related Au(I) complexes, [Au(eppe)2]CI and [Au(dppe)2]CI showed almost no
mitochondrial selectivity in the same screening protocol.30 Previous studies have shown that
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[Au(dppe)2]CI disrupts the membrane potential in mitochondria and uncouples oxidative
phosphorylation, resulting in severe hepato-, cardio- and vascular toxicity.31 33 In isolated rat liver
mitochondria, [Au(dppe)2]+ dissipated the membrane potential of the mitochondria, thereby
uncoupling oxidative phosphorylation. This is possibly due to increased permeability of the inner
membrane to cations and protons.31 In rabbits this also occurred and ATP synthesis was shown to
be reduced and mitochondrial defects were evident, eventually leading to death by cardiotoxicity.32
Similar results were obtained in a pre-clinical trial of [Au(dppe)2] lactate, which was terminated due
to cardio-, hepato- and vascular toxicity.33 Although mitochondria appear to be a target site for the
Au(I) complexes, our studies indicate that these complexes are not mitochondrially selective. It is
also noteworthy that the [Au(dppe)2]CI concentrations of 12.5- 100 #M used in the isolated rat
mitochondria studies were much higher than those used in our yeast studies (< 12.5 #M). Therefore
it is possible that the acute toxicity observed for [Au(dppe)2]CI is related to the relatively high dose
administered. As [Ag(eppe)2]NO3 is antimitochondrially-active at much lower doses, it may prove to
be a more useful chemotherapeutic agent. The higher activity may also be related to the higher
water solubility of the silver complex compared to the gold complex, which should result in less
accumulation in membranes and therefore greater potency. It is possible that Ag(I) complexes,
particularly, [Ag(eppe)2]NO3, which show primary antimitochondrial toxicity, will be useful
antitumour agents because they can attack the defective mitochondria of the tumour cells at
sufficiently low doses, and destroy the tumour, with less damage being done to healthy cells. It is
well known that cancer cells generally have low respiratory rates and high glycolytic activity.9 The
effect of aspirin in preventing the activity of anticancer drugs may be of importance clinically, since
this analgesic is liberally prescribed for cancer patients undergoing chemotherapy.
CONCLUSIONS
The therapeutic use of silver compounds, at present, is limited to topical preparations for
antiseptic purposes. The studies reported here show that tetrahedral silver diphosphine complexes,
such as [Ag(eppe)2]NO3, show primary antimitochondrial activity, and may be useful as antitumour
agents, selectively targeting the respiratory-deficient mitochondria in cancer cells.9 The choice of
ligands and metal appear to be important in controlling this activity. Although the reactivity of the
silver compound with components of serum is noted, it may be possible to overcome this with a
formulation which delivers the silver complex directly to cancer cells. In addition, the reversal of the
effect with aspirin has obvious clinical implications.
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